2011 Update
It looks like the mini-correction is over. Many stocks in our model portfolio are up 5% and more since 12/31/10 but we are still below peak values of mid-January .
Laggards are CEPH, MITI and NKTR. Look at doubling down on Cephalon (CEPH) which is at its five year low and priced at ~2X Sales but with negative growth estimates. Nektar (NKTR) requires more detailed analysis and the technicals still do not look good.
New buys for 2011 are Albany Molecular (AMRI) and Optimer (OPTR).
| 2010 | Price | Original | P | Price | % Ret | Price | |
| 7/2/10 | Recomm | YrEnd’10 | 2010 | 3/3/11 | |||
| Alexion | ALXN | 50.45 | 2/2/09 | 35 | 80.55 | 130 | 98.4 |
| Albany Molec | AMRI | 2/10/11 | 4.7 | added | 4.55 | ||
| Ardea Biosci | RDEA | 19.5 | 2/2/09 | 12 | 26 | 117 | 26.9 |
| Amgen | AMGN | 51.7 | 2/2/09 | 55 | 54.9 | 0 | 52.15 |
| Biogen | BIIB | 49.42 | 2/2/09 | 49 | 67.05 | 37 | 71.41 |
| Cephalon | CEPH | 55.95 | 2/2/09 | 77 | 61.72 | -19 | 57.75 |
| Cubist | CBST | 20.7 | 2/2/09 | 22 | 21.4 | -3 | 22 |
| Exelixis | EXEL | 9/2/10 | 3.3 | 8.21 | 148 | 12.3 | |
| First Trust ETF | FBT | 30.4 | 4/15/10 | 38 | 39.11 | 3 | 38.83 |
| Gilead | GILD | 34.9 | 2/2/09 | 51 | 36.24 | -29 | 39.65 |
| iShares ETF | IBB | 76.6 | 2/2/09 | 71 | 93.42 | 32 | 96.1 |
| Micromet | MITI | 6.28 | 2/2/09 | 4 | 8.12 | 103 | 5.8 |
| Nektar | NKTR | 11.6 | 4/15/10 | 15 | 12.85 | -14 | 8.7 |
| Optimer | OPTR | 2/18/11 | 12 | added | 11.65 | ||
| Regeneron | REGN | 21.6 | 2/2/09 | 18 | 32.83 | 82 | 37.38 |
| Seattle Genom. | SGEN | 11.85 | 2/2/09 | 9.5 | 14.95 | 57 | 14.93 |
| Supergen | SUPG | 2 | 2/2/09 | 2.3 | 2.62 | 14 | 3 |
| Targacept | TRGT | 19.42 | 2/2/09 | 2.2 | 26.5 | 1104 | 29.67 |
| United Rx | UTHR | 48.7 | 2/2/09 | 34 | 63.22 | 86 | 69.78 |
| ViroPharma | VPHM | 10.88 | 2/2/09 | 12 | 17.32 | 44 | 18.36 |